Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Basilea Pharmaceutica AG    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Basilea announces change in the Management Committee - Adesh Kaul appointed CFO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2019 | 01:16am EDT

Basel, February 7, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Board of Directors has appointed Adesh Kaul, currently Chief Corporate Development Officer and member of the Management Committee, as the new Chief Financial Officer (CFO) as of April 10, 2019. He will succeed Donato Spota, who has decided to pursue a new opportunity outside the company. Mr. Spota will continue in his role until the Annual General Meeting on April 10, 2019.

David Veitch, CEO of Basilea, said: "In Adesh Kaul we have an excellent CFO. He brings a wealth of experience in corporate finance, business development and investor relations. His profound understanding of the pharmaceutical industry and financial experience are highly relevant for the future financial leadership of our company. Adesh's long-standing career at Basilea and knowledge as an existing member of the Management Committee will ensure a seamless transition."

He added: "Following a 16-year career at Basilea, we would like to thank Donato for his commitment and significant contributions and we wish him every success for the future."

CV Adesh Kaul

Adesh Kaul is a Swiss citizen. He is currently the Chief Corporate Development Officer and is a member of the Management Committee of Basilea. Mr. Kaul previously held the position of Head of Corporate Development. He joined Basilea in 2009 and served as Head Business Development, Licensing & Investor Relations and as Head Public Relations & Corporate Communications. From 2015 to 2016, he held the positions of CFO and Head Corporate Development at Polyphor AG. From 2006 to 2009 Mr. Kaul was senior financial analyst at Neue Zürcher Bank and before that he held several senior executive positions in general management and in sales & marketing at Genedata AG.

Mr. Kaul holds master's degrees in economics and in biochemistry from the University of Basel, and an Executive MBA from the University of St. Gallen.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
+41 61 606 1102
media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com

Attachment


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BASILEA PHARMACEUTICA AG
07/01Basilea extends phase 2 study with derazantinib in intrahepatic bile duct can..
GL
06/03Basilea reports publication of clinical data for anticancer drug candidates B..
GL
05/02BASILEA PHARMACEUTICA : partner Avir Pharma has launched antifungal Cresemba® (i..
AQ
04/24BASILEA PHARMACEUTICA : Forge And Basilea Enter Into Multi-Target Agreement To D..
PR
04/10BASILEA PHARMACEUTICA : shareholders approve all proposals of the Board of Direc..
AQ
02/19BASILEA PHARMACEUTICA : reports strong revenue growth and significant pipeline p..
AQ
02/08Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milesto..
GL
02/07BASILEA PHARMACEUTICA : announces change in the Management Committee - Adesh Kau..
GL
02/07Basilea announces change in the Management Committee - Adesh Kaul appointed C..
GL
01/25Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecen..
AQ
More news
Financials (CHF)
Sales 2019 133 M
EBIT 2019 -25,5 M
Net income 2019 -31,4 M
Debt 2019 40,7 M
Yield 2019 -
P/E ratio 2019 -13,0x
P/E ratio 2020 -127x
EV / Sales2019 3,34x
EV / Sales2020 3,02x
Capitalization 404 M
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 85,1  CHF
Last Close Price 37,6  CHF
Spread / Highest target 262%
Spread / Average Target 127%
Spread / Lowest Target 41,0%
EPS Revisions
Managers
NameTitle
David Veitch Chief Executive Officer
Domenico Scala Chairman
Donato Spota Chief Financial Officer
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BASILEA PHARMACEUTICA AG-5.96%403
IQVIA HOLDINGS INC35.46%31 409
LONZA GROUP28.39%25 111
CELLTRION, INC.--.--%20 827
INCYTE CORPORATION27.99%17 419
EXACT SCIENCES CORPORATION84.14%15 001